E2MC, as a returning investment partner in the ISS National Lab's Orbital Edge Accelerator, is investing in Micro-gRx, a startup harnessing microgravity to biomanufacture cell-free nanomedicines for heart disease.
Micro-gRx is focused on developing regenerative nanomedicine therapies that leverage microgravity to enhance manufacturing consistency and therapeutic output
Micro-gRx is focused on developing regenerative nanomedicine therapies that leverage microgravity to enhance manufacturing consistency and therapeutic output.